MCI
NKTR icon

McDonald Capital Investors’s Nektar Therapeutics NKTR Stock Holding History

McDonald Capital Investors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-767
Closed -$141K – 24
2016
Q4 		$141K Hold
767
– – 0.01% 20
2016
Q3 		$198K Sell
767
-300
-28% -$77.2K 0.02% 22
2016
Q2 		$228K Hold
1,067
– – 0.02% 19
2016
Q1 		$220K Hold
1,067
– – 0.02% 20
2015
Q4 		$270K Sell
1,067
-65
-6% -$13.4K 0.03% 20
2015
Q3 		$186K Hold
1,132
– – 0.02% 27
2015
Q2 		$212K Hold
1,132
– – 0.02% 25
2015
Q1 		$187K Hold
1,132
– – 0.02% 21
2014
Q4 		$263K Sell
1,132
-21
-2% -$4.49K 0.03% 21
2014
Q3 		$209K Sell
1,153
-80
-6% -$15.3K 0.02% 21
2014
Q2 		$237K Buy
1,233
+80
+7% +$14.1K 0.03% 18
2014
Q1 		$210K Hold
1,153
– – 0.03% 19
2013
Q4 		$196K Sell
1,153
-47
-4% -$7.58K 0.02% 19
2013
Q3 		$188K Sell
1,200
-153
-11% -$28.3K 0.02% 19
2013
Q2 		$234K Buy
+1,353
New +$208K 0.03% 20

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

McDonald Capital Investors's NKTR Position: Q1 2017 in Review

McDonald Capital Investors sold out of Nektar Therapeutics (NKTR) in Q1 2017, closing a stake of 767 shares — an estimated $141K sold.

McDonald Capital Investors first reported a position in NKTR in Q2 2013 and held it in 15 quarters. The position peaked at $270K in Q4 2015. 201 funds tracked by Wall St. Rank hold NKTR as of Q1 2017.

  • McDonald Capital Investors reported no remaining Nektar Therapeutics position as of Q1 2017 after selling out during the quarter.
  • McDonald Capital Investors sold 767 Nektar Therapeutics shares in Q1 2017, an estimated $141K.
  • McDonald Capital Investors first reported a position in Nektar Therapeutics in Q2 2013 and held it in 15 quarters.
  • McDonald Capital Investors's Nektar Therapeutics position peaked at $270K in Q4 2015.
  • 201 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2017.

Based on McDonald Capital Investors's 13F filing for Q1 2017, filed 2 May 2017.